Lloyd M Hutchinson

Dr. Lloyd M Hutchinson


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2016 in Histopathology
Verified
Journal Article
Closed access
PDF file
MKMichal Kamionek
Michal Kamionek
PMParnian Ahmadi Moghaddam
Parnian Ahmadi Moghaddam
Ali SakhdariAli Sakhdari
Ali Sakhdari
AKAlexandra E Kovach
Alexandra E Kovach
MWMatthew Welch
Matthew Welch
LHLloyd M Hutchinson
Lloyd M Hutchinson

19 April 2018 in JCI Insight
Verified
Journal Article
Open access
PDF file
SZSha Zhu
Sha Zhu
BWB. Marie Ward
B. Marie Ward
JYJun Yu
Jun Yu
AMAsia N. Matthew-Onabanjo
Asia N. Matthew-Onabanjo
JJJenny Janusis
Jenny Janusis
LSLeslie M. Shaw
Leslie M. Shaw
Pleomorphic invasive lobular carcinoma (PILC) is an aggressive variant of invasive lobular breast cancer that is associated with poor clinical outcomes. Limited molecular data are available to explain the mechanistic basis for PILC behavior. To address this issue, targeted sequencing was performed to identify molecular alterations that define PILC. This sequencing analysis identified genes that distinguish PILC from classic ILC and invasive ductal carcinoma by the incidence of their genomic changes. In particular, insulin receptor substrate 2 ( IRS2 ) is recurrently mutated in PILC, and pathway analysis reveals a role for the insulin receptor (IR)/insulin-like growth factor-1 receptor (IGF1R)/IRS2 signaling pathway in PILC. IRS2 mutations identified in PILC enhance invasion, revealing a role for this signaling adaptor in the aggressive nature of PILC.

18 June 2019 in Oncotarget
Verified
Journal Article
Open access
Ali SakhdariAli Sakhdari
Ali Sakhdari
PMParnian Ahmadi Moghaddam
Parnian Ahmadi Moghaddam
COChi Young Ok
Chi Young Ok
OWOtto Walter
Otto Walter
KTKeith Tomaszewicz
Keith Tomaszewicz
ECEdiz F. Cosar
Ediz F. Cosar
Oncotarget | https://doi.org/10.18632/oncotarget.26999 Ali Sakhdari, Parnian Ahmadi Moghaddam, Chi Young Ok, Otto Walter, Keith Tomaszewicz, Mandi-Lee Caporelli, Xiuling Meng, Jennifer LaFemina, Giles Whalen,...

1 March 2019 in Human Pathology
Verified
Journal Article
Closed access
XZXiaoqin Zhu
Xiaoqin Zhu
MSMohammed Salhab
Mohammed Salhab
KTKeith Tomaszewicz
Keith Tomaszewicz
XMXiuling Meng
Xiuling Meng
CMCarol Mathew
Carol Mathew
LHLloyd M Hutchinson
Lloyd M Hutchinson

8 September 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
HJHarish P. Janardhan
Harish P. Janardhan
KDKaren Dresser
Karen Dresser
LHLloyd M Hutchinson
Lloyd M Hutchinson
CTChinmay M. Trivedi
Chinmay M. Trivedi
Lymphangiectasia, an anomalous dilation of lymphatic vessels first described in the 17th century, is frequently associated with chylous effusion, respiratory failure, and high mortality in young patients, yet the underlying molecular pathogenesis and effective treatments remain elusive. Here, we identify an unexpected causal link between MAPK activation and defective development of the lymphatic basement membrane that drives lymphangiectasia. Human pathological tissue samples from patients diagnosed with lymphangiectasia revealed sustained MAPK activation within lymphatic endothelial cells. Endothelial KRAS G12D –mediated sustained MAPK activation in newborn mice caused severe pulmonary and intercostal lymphangiectasia, accumulation of chyle in the pleural space, and complete lethality. Pathological activation of MAPK in murine vasculature inhibited the Nfatc1-dependent genetic program required for laminin interactions, collagen crosslinking, and anchoring fibril formation, driving defective development of the lymphatic basement membrane. Treatment with ravoxertinib, a pharmacological inhibitor of MAPK, reverses nuclear-to-cytoplasmic localization of Nfatc1, basement membrane development defects, lymphangiectasia, and chyle accumulation, ultimately improving survival of endothelial KRAS mutant neonatal mice. These results reveal defective lymphatic basement membrane assembly and composition as major causes of thoracic lymphangiectasia and provide a potential treatment.

1 August 2021 in Annals of Diagnostic Pathology
Verified
Journal Article
Closed access
SMSepideh Madahian
Sepideh Madahian
RJRichard Judelson
Richard Judelson
XZXiaoqin Zhu
Xiaoqin Zhu
XMXiuling Meng
Xiuling Meng
KDKaren Dresser
Karen Dresser
JBJacob R. Bledsoe
Jacob R. Bledsoe